Viatris (NASDAQ:VTRS) shares are in focus today after the global healthcare major announced its results for the fourth quarter and increased its share repurchase program by $1 billion to $2 billion. In Q4, Viatris’ revenue declined by 1% year-over-year to $3.83 billion. The figure fell short of expectations by $80 million. Adjusted EBITDA for the quarter declined by 8% to $1.12 billion.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
However, after adjusting for divestitures, the company’s Q4 revenue ticked up by 1%. Similarly, its net sales in the Emerging Markets and Greater China segments increased by 14% and 2%, respectively. However, the company saw a decline of 1% in net sales from Developed Markets. For Fiscal Year 2024, Viatris expects total revenue in the range of $15.25 billion to $15.75 billion. Adjusted EPS for the year is anticipated in the range of $2.70 to $2.85.
Further, Viatris pared down its debt by $1.25 billion in 2023. With an eye on maximizing shareholder value, the company is increasing its share repurchase program by $1 billion to $2 billion. Additionally, Viatris declared a quarterly dividend of $0.12 per share. The VTRS dividend is payable on March 18 to investors of record on March 11.
Separately, Viatris has entered into a global research and development collaboration with Switzerland-based healthcare company Idorsia (GB:0RQE). This move adds two Phase Three assets, Selatogrel and Cenerimod, to VTRS’ product pipeline.
Is VTRS a Good Stock to Buy?
Viatris’ share price has rallied by nearly 22% over the past six months. Bank of America’s Jason Gerberry, the sole analyst tracking Viatris, has reiterated a Sell rating on the stock alongside a $10 price target. However, the Street’s views on the stock could see a revision following today’s earnings report.
Read full Disclosure